Accelr8's Q2 Revenues Drop Sharply As Novartis Deal Ends

Mar 21, 2012

NEW YORK (GenomeWeb News) – Accelr8 reported last week that its fiscal second-quarter revenues plummeted to $8,328 from $313,568 a year ago as a result of the expiration of an agreement with Novartis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in Nucleic Acids Research

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

Round and Round We Go

A BMJ study says that about half of former hematology-oncology regulators now work for industry.

Goodbye and Godspeed

Science should wish PhDs who leave academia well, a Nature editorial says.

New Baby Boy

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.

Main menu